Slides
Page 1
Helen Giza CEO & Chair of the Management Board Martin Fischer CFO August 4, 2026 Q2 2026 Earnings Call
Page 2
Safe harbor statement: In this Safe harbor statement, “the Company” and “Fresenius Medical Care” refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conversion of legal form. This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in the Company’s Annual Report on Form 20-F under the headings “Forward-Looking Statements” and “Risk Factors” and under the headings in that report referred to therein, and in the Company’s other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse). Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations. If not mentioned differently the term net income refers to the net income attributable to the shareholders of Fresenius Medical Care. Amounts are in Euro if not mentioned otherwise. Implementation of measures as presented herein may be subject to information and consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.
Page 3
Q2 2026 Highlights Q2 2026 Business Update Outlook 1 2 3
Page 4
Q4 2024 Conference Call Page 4 Strong earnings growth driven by Care Delivery Investor Relations | Analyst Presentation Q2 2026 1 Organic growth represents growth in revenue, adjusted for certain reconciling items including revenue from acquisitions, closed or sold operations and differences in dialysis days and presented at constant currency. 2 Adjusted for special items, growth at cc; reconciliation table for special items and currency to reported growth rates: page 20. Q2 2026 Solid organic revenue growth¹ of 5% driven by all segments Strong operating income² growth of 23% and operating income margin² expansion to 11.7% FME25+ program savings of €67 million contributed to earnings growth Share buyback program executed at pace, successful completion of the first and initiating second €1 billion program Stable net financial leverage ratio of 2.6x maintained around the lower end of the target corridor FY 2026 outlook confirmed
Page 5
Q4 2024 Conference Call Page 5 Q2 2026 Highlights | Focused execution of FME Reignite strategy Investor Relations | Analyst Presentation Q2 2026 1 Adjusted for special items; Reconciliation table for special items and currency to reported growth rates: page 20. ▪ Same market treatment growth in − U.S. -0.9% − International +0.8% ▪ Accelerating momentum − Accelerating rollout of 5008X CAREsystem − Around 100 selected U.S. clinics exited − Favorable rate and increasing contributions from revenue cycle management − Declining blood stream infection rate and improving mortality ▪ Continued positive operating income¹ driven by improvement in payer savings rate ▪ Increased number of member months due to contract expansion ▪ Improved outcomes for FME dialysis patients managed by Interwell Health ▪ FME VBC expert call planned for October 12 ▪ Favorable business growth from accelerating 5008X CAREsystem sales ▪ Continued positive pricing and volume development outside China ▪ Negative impacts from regulatory policy changes in China and increased cost inflation driven by Middle East conflict ▪ Continued FME25+ progress ▪ Product launches of TherapyWiseTM analytics and kinexusTM digital platform for Home Dialysis Care Delivery Care EnablementValue-Based Care
Page 6
Q4 2024 Conference Call Clinics & machines 227 clinics converted in 23 of the planned 28 states 10% of planned 20% machines replaced Positive experience for patients and clinicians ▪ Patients report feeling better during and after dialysis ▪ Preliminary data show 40% fewer muscle cramps ▪ Over 70% of treatments1 already reach the HVHDF target of 23 liters of convective volume per session ▪ Based on clinician reports, the technology´s intelligent automation simplifies workflows and helps optimize clinic resources, while creating a much quieter treatment environment for patients and staff BEACON-US to advance clinical evidence ▪ Research initiative to evaluate clinical outcomes and patient experiences of HVHDF in routine U.S. clinical practice across diverse patient populations ▪ Early observations are tracking consistently with previously published international, randomized and real-world studies, including landmark, EU-funded CONVINCE study Encouraging early U.S. experience with HVHDF 2026 U.S. 5008X CAREsystem rollout progressing as planned Investor Relations | Analyst Presentation Note: All data related to U.S. rollout of 5008X CAREsystem in FME clinics by July 24, 2026; numbers rounded | 1 According to the BEACON-US research cohort, treatments using AutoSub plus technology Consumables 4m of up to 17m consumables units shipped/produced Patients & treatments 6k patients transitioned 600k treatments performed, thereof 170k HDF / 100k HVHDF Training 5k of over 7k renal nurses and patient care technicians trained Page 6Q2 2026 2026 year-to-date progress vs. plan
Page 7
Q2 2026 Highlights Q2 2026 Business Update Outlook 1 2 3
Page 8
Q4 2024 Conference Call Q2 2025 Q2 2026 4,792 4,861 +3.6% at cc¹ ▪ Operating income growth¹ driven by Care Delivery and Value-Based Care ▪ Special items mainly include costs related to Tavneos® impacts and FME25+ program ▪ Solid organic revenue growth of 5% driven by all segments ▪ Care Enablement growth negatively impacted by China business ▪ Divestitures negatively impacted growth by approx. 50 bps Page 8 Q2 2026 | Significant operating income growth and margin expansion Investor Relations | Analyst Presentation Q2 2026 1 At cc = at constant currency; operating income (growth) excluding special items | Q2 2026 €588 million operating income excl. special items at cc | Reconciliation table for special items and currency to reported growth rates: page 20. 2 Organic growth represents growth in revenue, adjusted for certain reconciling items including revenue from acquisitions, closed or sold operations and differences in dialysis days and presented at constant currency. Revenue in € million Operating income in € million 8.9% 9.9% 11.7% 9.6% Margin in % +4.9% organic2 +1.4% as reported 425 476 569 46651 Q2 2025 Special items Q2 2025 excl. special items Q2 2026 excl. special items Special items Q2 2026 -103 +23.5% at cc1 +19.6% at current rate
Page 9
Q4 2024 Conference Call Page 9 Q2 2026 | Step up in profitability mainly driven by Care Delivery Investor Relations | Analyst Presentation Q2 2026 425 476 569 46651 170 28 Q2 2025 operating income Special items Q2 2025 operating income excl. special items Care Delivery Value-Based Care Care Enablement Inter- segment Corporate Fx translation Q2 2026 operating income excl. special items Special items Q2 2026 operating income -6 -33 -47 -19 -103 Reconciliation table for special items and currency to reported growth rates: page 20. Margin in %in € million 9.9% 11.7%
Page 10
Q4 2024 Conference Call 564 581 Q2 2025 Q2 2026 3,381 3,478 2,817 2,897 +5.5% at cc¹ 378 527169 39 Q2 2025 excl. special items Business growth FME25+ savings Labor / Inflation Fx translation Q2 2026 excl. special items -38 -21 +45.3% at cc1 ▪ Underlying improvement of 34% (excl. TDAPA) ▪ Business growth supported by − underlying operating income improvement driven by favorable rate effects − further increased benefits from TDAPA reimbursement regulations ▪ U.S. organic growth of 7% driven by positive impact from TDAPA reimbursement regulations, favorable rate effects as well as reduced implicit price concessions ▪ Solid organic growth in International business ▪ Divestitures negatively impacted growth by approx. 90 bps Revenue in € million Page 10 Q2 2026 | Care Delivery accelerates profitable growth Investor Relations | Analyst Presentation Q2 2026 1 At cc = at constant currency; operating income (growth) excluding special items | Q2 2026 €548 million operating income excl. special items at cc | Reconciliation table for special items and currency to reported growth rates: page 20 2 Organic growth represents growth in revenue, adjusted for certain reconciling items including revenue from acquisitions, closed or sold operations and differences in dialysis days and presented at constant currency. Operating income in € million Margin in % 11.2% 15.1% U.S. International +7.4% organic2 +2.9% as reported +39.5% at current rate
Page 11
Q4 2024 Conference Call 506 536 Q2 2025 Q2 2026 +9.0% at cc¹ -9 184 Q2 2025 excl. special items Business growth FME25+ savings Inflation Fx translation Q2 2026 excl. special items 25 -1 -1 n.a. at cc1 ▪ Business growth mainly driven by improved savings rate ▪ FME25+ supported by integration synergies ▪ Organic revenue growth mainly driven by a higher number of member months and a positive effect from premium rates, partly offset by the changed risk contracting for one contract Page 11 Q2 2026 | Value-Based Care delivers positive operating income Investor Relations | Analyst Presentation Q2 2026 1 At cc = at constant currency; operating income (growth) excluding special items | Q2 2026 €19 million operating income excl. special items at cc | Reconciliation table for special items and currency to reported growth rates: page 20 2 Organic growth represents growth in revenue, adjusted for certain reconciling items including revenue from acquisitions, closed or sold operations and differences in dialysis days and presented at constant currency. Revenue in € million Operating income in € million Margin in % -1.7% 3.3% +9.0% organic2 +6.0% as reported
Page 12
Q4 2024 Conference Call Q2 2025 Q2 2026 1,348 1,371 +2.7% at cc¹ 117 111 13 21 Q2 2025 excl. special items Business growth FME25+ savings Inflation Fx translation Q2 2026 excl. special items -40 0 -4.8% at cc1 ▪ Solid organic revenue growth based on overall positive pricing, despite adverse regulatory impacts in China ▪ Growing positive impact from sales of 5008X CAREsystems ▪ Business growth driven by − positive volume and price effects outside China − adverse regulatory impacts in China ▪ Increased cost inflation driven by the Middle East conflict ▪ Continued FME25+ progress in manufacturing and supply chain Page 12 Q2 2026 | Care Enablement grows revenue despite China business Investor Relations | Analyst Presentation Q2 2026 1 At cc = at constant currency; operating income (growth) excluding special items | Q2 2026 €111 million operating income excl. special items at cc | Reconciliation table for special items and currency to reported growth rates: page 20 2 Organic growth represents growth in revenue, adjusted for certain reconciling items including revenue from acquisitions, closed or sold operations and differences in dialysis days and presented at constant currency. Revenue in € million Operating income in € million Margin in % 8.7% 8.1% +2.7% organic2 +1.7% as reported -5.5% at current rate
Page 13
Q4 2024 Conference Call Page 13 2023 2024 2025 Q2 2026 Q2 2026 | Strong operating cash flow growth and low leverage ratio Investor Relations | Analyst Presentation Q2 2026 in € million Q2 2026 Q2 2025 ∆ in % H1 2026 H1 2025 ∆ in % Operating cash flow 860 775 11 1,087 938 16 ▪ Capital expenditures, net -235 -147 61 -422 -289 46 Free cash flow 625 628 -1 665 649 2 ▪ Free cash flow after investing activities 590 633 -7 647 688 -6 Total net debt and lease liabilities 9,902 9,315 6 9,902 9,315 6 3.2x 2.9x 2.6x 2.5x Key developments ▪ Operating cash flow increased mainly driven by favorable working capital development ▪ Total debt and lease liabilities (€11.0 billion) as well as total net debt and lease liabilities (€9.9 billion) as expected ▪ 2.5 million shares or 0.9% of share capital repurchased (€94 million) under second €1 billion share buyback program ▪ Net leverage ratio maintained around the lower end of the target corridor Net leverage ratio (Net debt/EBITDA) Previous target corridor: 3.0x-3.5x Target corridor: 2.5x-3.0x
Page 14
Q2 2026 Highlights Q2 2026 business update Outlook 1 2 3
Page 15
Q4 2024 Conference Call Page 15 FY 2026 | Outlook confirmed Investor Relations | Analyst Presentation Q2 2026 Broadly flat FY 2025 basis: € 19,628 million Between positive and negative mid-single digit percent FY 2025 basis: € 2,212 million Operating Income growth Implied Group operating income margin 10.5 – 12.0% Revenue growth FY 2026 Revenue and Operating Income Revenue and operating income, as referred to in the outlook, are both on a constant currency basis and excluding special item s. Special items will be provided as separate KPI (“Operating income excl. special items”) to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. Th ese items are excluded to ensure comparability of the figures presented with the Company’s financial targets which have been defined excluding special items. Growth is measured year-on-year. The outlook assumes current laws/policies/regulations and tariffs. See page 20 for reconciliation table for special items
Page 16
Your questions are welcome.
Page 17
Appendix
Page 18
Q4 2024 Conference Call Page 18 Q2 2026 | Profit and Loss Investor Relations | Analyst Presentation Q2 2026 Q2 2026 € million Q2 2025 € million Growth in % Growth in % cc Revenue 4,861 4,792 1 4 Operating income 466 425 10 15 Operating income margin in % 9.6 8.9 Operating income excl. special items 569 476 20 23 Operating income margin excl. special items in % 11.7 9.9 Net interest expense 83 75 11 12 Income before taxes 383 350 9 16 Income tax expense 90 78 15 22 Tax rate in % 23.5 22.3 Non-controlling interest 75 47 59 66 Net income¹ 218 225 -3 3 Net income excl. special items¹ 303 268 13 17 1 Attributable to shareholders of FME AG; reconciliation table for special items and currency to reported growth rates: page 20
Page 19
Q4 2024 Conference Call Page 19 H1 2026 | Profit and Loss Investor Relations | Analyst Presentation Q2 2026 H1 2026 € million H1 2025 € million Growth in % Growth in % cc Revenue 9,473 9,673 -2 3 Operating income 752 757 -1 5 Operating income margin in % 7.9 7.8 Operating income excl. special items 1,036 933 11 17 Operating income margin excl. special items in % 10.9 9.6 Net interest expense 162 155 4 9 Income before taxes 590 602 -2 3 Income tax expense 133 139 -5 0 Tax rate in % 22.5 23.2 Non-controlling interest 121 87 43 53 Net income¹ 336 376 -11 -6 Net income excl. special items¹ 553 514 8 13 1 Attributable to shareholders of FME AG; reconciliation table for special items and currency to reported growth rates: page 21
Page 20
Q4 2024 Conference Call Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures for comparison with outlook Page 20 Q2 2026 | Reconciliation adjustments Investor Relations | Analyst Presentation Q2 2026 Group Care Delivery Value-Based Care Care Enablement Corporate Inter-segment eliminations € million Q2 2026 Q2 2025 in % Q2 2026 Q2 2025 in % Q2 2026 Q2 2025 in % Q2 2026 Q2 2025 in % Q2 2026 Q2 2025 Q2 2026 Q2 2025 Revenue 4,861 4,792 1 3,478 3,381 3 536 506 6 1,371 1,348 2 -- -- -524 -443 Operating Income 466 425 10 435 346 26 17 -9 n.a. 99 89 11 -46 7 -39 -8 FME25+ program 42 53 26 26 1 0 15 27 0 0 -- -- Humacyte remeasurements -7 -9 -- -- -- -- -3 1 -4 -10 -- -- Legacy portfolio optimization -3 6 -5 6 -- -- 0 0 2 -- -- -- Legal form conversion costs -- 1 -- -- -- -- -- -- -- 1 -- -- Tavneos impacts 71 -- 71 -- -- -- -- -- -- -- -- -- Sum of special items 103 51 92 32 1 -- 12 28 -2 -9 -- --- Operating income excl. special items 569 476 20 527 378 40 18 -9 n.a. 111 117 -6 -48 -2 -39 -8- Foreign currency translation 19 21 1 0 -1 -2 Operating income excl. Special items at cc 588 548 19 111 -49 -41
Page 21
Q4 2024 Conference Call Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures for comparison with outlook Page 21 H1 2026 | Reconciliation adjustments Investor Relations | Analyst Presentation Q2 2026 Group Care Delivery Value-Based Care Care Enablement Corporate Inter-segment eliminations € million H1 2026 H1 2025 in % H1 2026 H1 2025 in % H1 2026 H1 2025 in % H1 2026 H1 2025 in % H1 2026 H1 2025 H1 2026 H1 2025 Revenue 9,473 9,673 -2 6,772 6,828 -1 1,027 1,035 -1 2,670 2,715 -2 -- -- -996 -905 Operating Income 752 757 -1 706 666 6 6 -6 n.a. 186 183 1 -85 -74 -61 -12 FME25+ program 208 80 144 40 20 1 44 38 0 1 -- -- Humacyte remeasurements -4 65 -- -- -- -- -7 8 3 57 -- -- Legacy portfolio optimization 9 30 3 28 -- -- 1 2 5 -- -- -- Legal form conversion costs -- 1 -- -- -- -- -- -- -- 1 -- -- Tavneos impacts 71 -- 71 -- -- -- -- -- -- -- -- -- Sum of special items 284 176 218 68 20 1 38 48 8 59 -- --- Operating income excl. special items 1,036 933 11 924 734 26 26 -5 n.a. 224 231 -3 -77 -15 -61 -12 Foreign currency translation 53 75 2 2 -22 -4 Operating income excl. Special items at cc 1,089 999 28 226 -99 -65
Page 22
Q4 2024 Conference Call Page 22 Debt Investor Relations | Analyst Presentation Q2 2026 Q2 2026 € million FY 2025 € million FY 2024 € million Debt Short-term debt 1,741 1,613 577 + Current portion of lease liabilities 584 584 641 + Long-term debt, less current portion 5,825 5,692 6,261 + Lease liabilities, less current portion 2,813 2,906 3,500 + Debt and lease liabilities included within liabilities directly associated with assets held for sale -- -- 9 Total debt and lease liabilities 10,963 10,795 10,988 − Cash and cash equivalents1 -1,061 -1,599 -1,185 Total net debt and lease liabilities 9,902 9,196 9,803 1 Includes cash and cash equivalents included within assets held for sale
Page 23
Q4 2024 Conference Call Reconciliation of adjusted EBITDA and net leverage ratio to the most directly comparable IFRS financial measures Page 23 EBITDA Investor Relations | Analyst Presentation Q2 2026 LTM Q2 2026 € million FY 2025 € million FY 2024 € million Net income 1,187 1,191 741 + Income tax expense 314 321 316 − Interest income -62 -70 -72 + Interest expense 383 385 407 + Depreciation and amortization 1,430 1,463 1,536 + Adjustments1 539 447 450 Adjusted EBITDA 3,791 3,737 3,378 Net leverage ratio (Net debt/EBITDA) 2.6 2.5 2.9 1 Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in the Syndicated Credit Facility (2026: -€1 M; 2025: €1 M), non-cash charges, primarily related to pension expense (2026: €44 M; 2025: €47 M), impairment loss (2026: €127M; 2025: €37 M), and special items, including costs related to the FME25+ Program (2026: €193 M; 2025: €185 M), Legacy Portfolio Optimization (2026: €82 M; 2025: €83 M), Legal Form Conversion Costs (2026: €2 M; 2025: €4 M), Humacyte Remeasurements (2026: €21 M; 2025: €90 M) and Tavneos® Impacts (2026: €71 M).
Page 24
Q4 2024 Conference Call Page 24 Return on Invested Capital (ROIC) Investor Relations | Analyst Presentation Q2 2026 ▪ ROIC in 2020 excl. the impact of the Latin America impairment (special item) and in 2021 excluding FME25+ (special item) ▪ ROIC for 2020 and 2021 was 7.5% and 5.5% excl. IFRS 16 and excl. Latin America impairment in 2020 ▪ ROIC in 2022 adjusted for the effects of the FME25+ program, the Humacyte Investment Remeasurement, the net gain related to InterWell Health, the effects of hyperinflation in Turkiye and impacts related to the war in Ukraine ▪ ROIC in 2023-2024 adjusted for the effects of the FME25+ program, Legal Form Conversion costs, Legacy Portfolio Optimization and Humacyte Remeasurements ▪ ROIC in 2025 adjusted for the effects of the FME25+ program, Legal Form Conversion costs, Legacy Portfolio Optimization, Humacyte Remeasurements and Interwell Health Deferred Tax Reversal ▪ ROIC in 2026 adjusted for the effects of the FME25+ program, Legacy Portfolio Optimization, Humacyte Remeasurements and Tavneos® Impacts 5.8% 6.6% 2020 4.9% 5.1% 2021 3.3% 3.9% 2022 2.8% 3.6% 2023 3.5% 4.5% 2024 5.0% 6.1% 2025 6.6% adj. Q2 2026 5.0% rep.
Page 25
Q4 2024 Conference Call Exchange rates Page 25 Exchange rates, U.S. dialysis days, vPPA, definitions Investor Relations | Analyst Presentation Q2 2026 H1 2026 FY 2025 FY 2024 €:USD Period end 1.139 1.175 1.039 Average 1.167 1.130 1.082 €:CNY Period end 7.731 8.226 7.583 Average 8.007 8.118 7.788 €:RUB Period end 89.352 93.980 115.968 Average 89.182 94.429 100.458 Q1 Q2 Q3 Q4 Full year 2026 76 78 79 79 312 2025 76 78 79 80 313 2024 77 78 79 80 314 2023 77 78 79 79 313 U.S. dialysis days per quarter Definitions cc at constant currency HD Hemodialysis PD Peritoneal dialysis Net income Net income attributable to shareholders of FME LTM Last-Twelve-Months Virtual power purchase agreements (vPPA) € million Q2 2026 Q2 2025 vPPA amount -14 15
Page 26
Q4 2024 Conference Call Page 26 Q2 2026 | Key metrics for Care Delivery and Value-Based Care Investor Relations | Analyst Presentation Q2 2026 as of June 30, 2026 as of June 30, 2025 Growth in % Care Delivery Patients 289,610 300,339 -4 United States 203,177 206,259 -1 International 86,433 94,080 -8 Treatments 21,521,790 22,314,266 -4 United States 15,150,505 15,327,129 -1 International 6,371,285 6,987,137 -9 Clinics 3,513 3,676 -4 United States 2,539 2,627 -3 International 974 1,049 -7 Value-Based Care – United States Member Months 927,045 869,968 +7 Membership 154,349 147,532 +5
Page 27
Q4 2024 Conference Call Quality index components Page 27 Continuous monitoring of clinical performance to enhance care Investor Relations | Analyst Presentation Q2 2026 Quality index Global indicator for patient well-being and treatment success Dialysis effectiveness Measures how sufficiently the body is cleansed of waste substances Vascular access Measures the share of patients who do not receive dialysis via a dialysis catheter but rather via safer vascular access alternatives that reduce risk of infection and improve outcomes Anemia management Measures hemoglobin levels and specific medications given during dialysis to achieve optimum clinical outcomes, such as overall health and well-being Q2 2026 Q1 2026 Quality index 80% 80% Dialysis effectiveness 93% 93% Vascular access 75% 75% Anemia management 71% 71%
Page 28
Q4 2024 Conference Call Page 28 IR event calendar Investor Relations | Analyst Presentation Q2 2026 Reporting & AGM Conferences/Roadshows August 04 Virtual Report on Q2 2026: Earnings Release and Conference Call September 01 - 02 US West Cast IR Roadshow 01 Frankfurt Commerzbank | ODDO BHF Corporate Conference 07 Frankfurt BNP Paribas Exane Bus Tour 08 Boston Wells Fargo Conference 09 London Goldman Sachs European MedTech & HC Conference 14 New York Morgan Stanley Global HC Conference 22 München Berenberg | GS German Corporate Flagship Conference 21 München Baader Investment Conference 23 London Bank of America Global Healthcare Conference 30 Tokyo Mizuho's Asian Investor Conference November 20.10. – 02.11. Quiet Period HC = Healthcare 05 Virtual Q2 Roadshow 26 Stockholm IR Roadshow 03 Netherlands IR Roadshow 09 - 10 Toronto, Montreal IR Roadshow 15 Milwaukee, Chicago IR Roadshow October 04 London Q3 Roadshow 03 Virtual Report on Q3 2026: Earnings Release and Conference Call 10 Palm Beach UBS Global Healthcare Conference 11 - 12 San Francisco, Chicago Q3 Roadshow 17 Frankfurt DZ Equity Conference 05 Frankfurt Q3 Roadshow 18 London Jefferies Healthcare Conference 01 Madrid Berenberg Madrid Seminar
Page 29
Ilia Kuerten Vice President Investor Relations +49(0) 6172-268 5966 Ilia.Kuerten@ FreseniusMedicalCare.com Alicia Cahill Senior Director Investor Relations +1 860-609-2394 Alicia.Cahill@ FreseniusMedicalCare.com Dr. Dominik Heger Global Head of Investor Relations, Market & Competition, Sustainability | EVP +49(0) 6172-2685-822 Dominik.Heger@ FreseniusMedicalCare.com Gari Hoto Senior Manager Investor Relations +49(0) 6172-268-6078 Garikai.Hoto@ FreseniusMedicalCare.com Fresenius Medical Care AG Investor Relations Else-Kröner-Str. 1 61352 Bad Homburg v. d. H. Germany ir@FreseniusMedicalCare.com Ticker: FME and FMS (NYSE/ADR) WKN: 578 580 ISIN: DE00057858002 CUSIP (ADR): 358029106